{
    "id": 2461,
    "fullName": "GATA2 wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type GATA2 indicates that no mutation has been detected within the GATA2 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2624,
        "geneSymbol": "GATA2",
        "terms": [
            "GATA2",
            "DCML",
            "IMD21",
            "MONOMAC",
            "NFE1B"
        ]
    },
    "variant": "wild-type",
    "createDate": "10/23/2014",
    "updateDate": "09/04/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1462,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of bortezomib and fasudil blocked GATA2 downstream signals in KRAS activated NSCLC cells, resulting in reduced tumor burden, size and number in treated mice (PMID: 22541434).",
            "molecularProfile": {
                "id": 2563,
                "profileName": "GATA2 wild-type KRAS mut"
            },
            "therapy": {
                "id": 1778,
                "therapyName": "Bortezomib + Fasudil",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1329,
                    "pubMedId": 22541434,
                    "title": "The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22541434"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2563,
            "profileName": "GATA2 wild-type KRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 7407,
            "profileName": "GATA2 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}